<DOC>
	<DOCNO>NCT02207348</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate bioequivalence single-dose liraglutide administer subcutaneously two different pen-injectors .</brief_summary>
	<brief_title>Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors</brief_title>
	<detailed_description />
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female , age 1860 year ( inclusive ) time sign informed consent Body mass index ( BMI ) great equal 27.0 less 35.0 kg/m^2 Bodyweight 130.0 kg ( inclusive ) HbA1c ( glycosylated haemoglobin ) 6.5 % Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method . Only highly effective method birth control accept ( i.e . one result less 1 % per year failure rate use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ) , sexual abstinence vasectomise partner History presence cancer , clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrine ( incl . diabetes ) , haematological , dermatological , venereal , neurological , psychiatric disease major disorder might impact trial , judge investigator Use prescription nonprescription medication , except paracetamol , acetylsalicylic acid , contraceptive vitamin ( include megadose vitamin therapy , judge investigator ) within 2 week trial define screen Significant history alcoholism drug/chemical abuse within 1 year screening , positive result urine drug screen alcohol breath test , consume 21 unit alcohol per week ( one unit alcohol equal 250 mL beer lager , one glass wine ( 120 mL ) , 20 mL spirit ) Smoking 5 cigarette , equivalent , per day unable refrain smoking inhouse period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>